华神科技(000790) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was CNY 206,595,617.51, representing a 39.11% increase compared to CNY 148,511,424.02 in the same period last year[3]. - The net profit attributable to shareholders decreased by 19.48% to CNY 9,433,788.66 from CNY 11,715,714.45 year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 33.59% to CNY 9,230,154.56, down from CNY 13,899,723.69[3]. - The net profit for the first quarter was CNY 8,621,028.17, compared to CNY 11,865,391.51 in the same period last year, reflecting a decrease of approximately 27%[18]. - The basic and diluted earnings per share were both CNY 0.0151, compared to CNY 0.0187 in the previous period, indicating a decrease of 19.3%[19]. - The total comprehensive income attributable to the parent company was CNY 9,433,788.66, down from CNY 11,715,714.45, reflecting a decline of 19.5%[19]. Cash Flow - The net cash flow from operating activities increased by 134.17% to CNY 19,660,473.69, compared to a negative cash flow of CNY 57,536,200.29 in the previous year[3]. - Cash inflows from operating activities totaled CNY 223,148,429.87, an increase of 14.1% from CNY 195,544,500.14 in the previous period[21]. - The net cash flow from investing activities was negative CNY 191,086,908.94, worsening from negative CNY 87,370,886.71 in the previous period[21]. - The cash and cash equivalents at the end of the period were CNY 129,570,886.12, down from CNY 234,189,880.71 at the end of the previous period, reflecting a decrease of 44.7%[22]. - The company reported a cash inflow from financing activities of CNY 27,659,959.66, with cash inflows from borrowings amounting to CNY 28,020,000.00[22]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,406,259,884.96, a 7.57% increase from CNY 1,307,282,000.53 at the end of the previous year[3]. - The company’s total liabilities increased to CNY 416,751,257.23 from CNY 327,644,146.36, reflecting a growth of about 27%[16]. - The company’s equity attributable to shareholders rose to CNY 986,261,207.17 from CNY 975,577,673.12, an increase of approximately 1.3%[16]. Research and Development - The company reported a significant increase in R&D expenses by 245.61%, amounting to CNY 506.92 million, due to increased investment in research and development[8]. - The company reported a significant increase in research and development expenses, which rose to CNY 7,133,097.95 from CNY 2,063,937.22, marking an increase of about 246%[18]. Expenses - The total operating costs amounted to CNY 196,927,814.86, up from CNY 130,601,415.61, indicating a year-over-year increase of about 51%[18]. - The company experienced a 41.40% decrease in selling expenses, totaling CNY 2,366.31 million, attributed to reduced marketing expenditures in the pharmaceutical sector[8]. Investments - The company acquired two subsidiaries, resulting in the recognition of goodwill due to the purchase price exceeding the fair value of identifiable net assets[7]. - The company plans to invest up to CNY 130 million in the construction of a health management center in Haikou, with a property area of approximately 7,960 square meters[12]. Other - The first quarter report was not audited, indicating that the financial figures are subject to further verification[23].